

December 11, 2010

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Annex N3

17 **ICCVAM/NICEATM BG1Luc4E2 ER TA – Bibliography for the ER Binding and**
18 **Transcriptional Activation Literature Update**

December 11, 2010

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 *[This page intentionally left blank]*
35

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 35 Akahori Y, Nakai M, Yamasaki K, Takatsuki M, Shimohigashi Y, Ohtaki M. 2008.
36 Relationship between the results of in vitro receptor binding assay to human estrogen
37 receptor alpha and in vivo uterotrophic assay: comparative study with 65 selected
38 chemicals. *Toxicol In Vitro* 22(1): 225-231.
- 39 Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, et al. 2008.
40 G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the
41 proliferative effects induced by atrazine in ovarian cancer cells. In: *Environ Health
Perspect*, 1648-1655. Epub 2008 Jul 1622.
- 43 Amita M, Takahashi T, Tsutsumi S, Ohta T, Takata K, Henmi N, et al. 2010. Molecular
44 mechanism of the inhibition of estradiol-induced endometrial epithelial cell proliferation
45 by clomiphene citrate. *Endocrinology* 151(1): 394-405.
- 46 Andersen HR, Bonefeld-Jorgensen EC, Nielsen F, Jarfeldt K, Jayatissa MN, Vinggaard
47 AM. 2006. Estrogenic effects in vitro and in vivo of the fungicide fenarimol. *Toxicology
letters* 163(2): 142-152.
- 49 Attardi BJ, Page ST, Hild SA, Coss CC, Matsumoto AM. 2010. Mechanism of action of
50 bolandiol (19-nortestosterone-3 β ,17 β -diol), a unique anabolic steroid with
51 androgenic, estrogenic, and progestational activities. *J Steroid Biochem Mol Biol* 118(3):
52 151-161.
- 53 Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. 1998.
54 Differential response of estrogen receptor alpha and estrogen receptor beta to partial
55 estrogen agonists/antagonists. *Mol Pharmacol* 54(1): 105-112.
- 56 Baumann RJ, Bush TL, Cross-Doersen DE, Cashman EA, Wright PS, Zwolshen JH, et al.
57 1998. Clomiphene analogs with activity in vitro and in vivo against human breast cancer
58 cells. *Biochem Pharmacol* 55(6): 841-851.
- 59 Berckmans P, Leppens H, Vangenechten C, Witters H. 2007. Screening of endocrine
60 disrupting chemicals with MELN cells, an ER-transactivation assay combined with
61 cytotoxicity assessment. *Toxicol In Vitro* 21(7): 1262-1267.
- 62 Berthier A, Girard C, Grandvillemin A, Muyard F, Skaltsounis AL, Jouvenot M, et al.
63 2007. Effect of 7-O-beta-D-glucopyranosylchrysin and its aglycone chrysin isolated from
64 *Podocytisus caramanicus* on estrogen receptor alpha transcriptional activity. In: *Planta
Med*, 1447-1451. Epub 2007 Oct 1419.
- 66 Berube G, Rabouin D, Perron V, N'Zemba B, Gaudreault RC, Parent S, et al. 2006.
67 Synthesis of unique 17 β -estradiol homo-dimers, estrogen receptors binding affinity
68 evaluation and cytocal activity on breast, intestinal and skin cancer cell lines. In:
69 *Steroids*, 911-921. Epub 2006 Aug 2017.
- 70 Bhat KPL, Kosmeder JW, 2nd, Pezzuto JM. 2001a. Biological effects of resveratrol.
71 *Antioxid Redox Signal* 3(6): 1041-1064.

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 72 Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. 2001b. Estrogenic
73 and antiestrogenic properties of resveratrol in mammary tumor models. *Cancer Research*
74 61(20): 7456-7463.
- 75 Bhat KPL, Pezzuto JM. 2001. Resveratrol exhibits cytostatic and antiestrogenic
76 properties with human endometrial adenocarcinoma (Ishikawa) cells. *Cancer Research*
77 61(16): 6137-6144.
- 78 Bhavnani BR, Tam SP, Lu X. 2008. Structure activity relationships and differential
79 interactions and functional activity of various equine estrogens mediated via estrogen
80 receptors (ERs) ERalpha and ERbeta. In: *Endocrinology*, 4857-4870. Epub 2008 Jul
81 4853.
- 82 Bonefeld-Jorgensen EC, Long M, Hofmeister MV, Vinggaard AM. 2007. Endocrine-
83 disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-
84 n-octylphenol in vitro: new data and a brief review. In: *Environ Health Perspect*, 69-76.
- 85 Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. 2000. Resveratrol acts as a mixed
86 agonist/antagonist for estrogen receptors alpha and beta. *Endocrinology* 141(10): 3657-
87 3667.
- 88 Buteau-Lozano H, Velasco G, Cristofari M, Balaguer P, Perrot-Applanat M. 2008.
89 Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer
90 cells through an estrogen receptor-dependent mechanism. In: *J Endocrinol*, 399-412.
- 91 Buterin T, Koch C, Naegeli H. 2006. Convergent transcriptional profiles induced by
92 endogenous estrogen and distinct
93 xenoestrogens in breast cancer cells. *Carcinogenesis* 27(8): 1567-1578.
- 94 Byford J, Shaw L, Drew M, Pope G, Sauer M, Darbre P. 2002. Oestrogenic activity of
95 parabens in MCF7 human breast cancer cells. *The Journal of Steroid Biochemistry &*
96 *Molecular Biology* 80: 49-60.
- 97 Choi SY, Ha TY, Ahn JY, Kim SR, Kang KS, Hwang IK, et al. 2008. Estrogenic
98 activities of isoflavones and flavones and their structure-activity relationships. *Planta
99 Med* 74(1): 25-32.
- 100 Chrzan BG, Bradford PG. 2007. Phytoestrogens activate estrogen receptor beta1 and
101 estrogenic responses in human breast and bone cancer cell lines. *Mol Nutr Food Res*
102 51(2): 171-177.
- 103 Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B, Jordan VC. 2002. Regulation of
104 estrogen target genes and growth by selective estrogen-receptor modulators in
105 endometrial cancer cells. *Gynecol Oncol* 85(3): 498-506.
- 106 Dayan G, Lupien M, Auger A, Anghel SI, Rocha W, Croisetiere S, et al. 2006.
107 Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of
108 estrogen receptor alpha. *Mol Pharmacol* 70(2): 579-588.

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 109 Di X, Yu L, Moore AB, Castro L, Zheng X, Hermon T, et al. 2008. A low concentration
110 of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor
111 interactions and proliferation in uterine leiomyoma cells. *Hum Reprod* 23(8): 1873-1883.
- 112 Escande A, Pillon A, Servant N, Cravedi J-P, Larrea F, Muhn P, et al. 2006. Evaluation
113 of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or
114 beta. *Biochemical Pharmacology* 71(10): 1459-1469.
- 115 Evans RM, Rahte S, Kortenkamp A. 2010. Inability to confirm estrogenicity of the
116 heterocyclic amine PhIP in two in vitro assays. *Toxicol In Vitro* 2009 Dec 29.
- 117 Freyberger A, Schmuck G. 2004. Screening for estrogenicity and anti-estrogenicity: a
118 critical evaluation of an MVLN cell-based transactivation assay. *Toxicology letters*
119 155(1): 1-13.
- 120 Freyberger A, Wilson V, Weimer M, Tan S, Tran HS, Ahr HJ. 2010. Assessment of a
121 robust model protocol with accelerated throughput for a human recombinant full length
122 estrogen receptor-alpha binding assay: Protocol optimization and intralaboratory assay
123 performance as initial steps towards validation. *Reprod Toxicol* 2010 Jan 13.
- 124 Fujimoto N, Jinno N, Kitamura S. 2004. Activation of estrogen response element
125 dependent transcription by thyroid hormone with increase in estrogen receptor levels in a
126 rat pituitary cell line, GH3. *J Endocrinol* 181(1): 77-83.
- 127 Fujita T, Kobayashi Y, Wada O, Tateishi Y, Kitada L, Yamamoto Y, et al. 2003. Full
128 activation of estrogen receptor alpha activation function-1 induces proliferation of breast
129 cancer cells. *J Biol Chem* 278(29): 26704-26714.
- 130 Gehm B, McAndrews J, Chien P, Jameson J. 1997. Resveratrol, a polyphenolic
131 compound found in grapes and wine,
132 is an agonist for the estrogen receptor. *Proc Natl Acad Sci USA* 94: 14138-14143.
- 133 Ghisari M, Bonefeld-Jorgensen EC. 2009. Effects of plasticizers and their mixtures on
134 estrogen receptor and thyroid hormone functions. *Toxicology letters* 189(1): 67-77.
- 135 Gomez E, Pillon A, Fenet H, Rosain D, Duchesne MJ, Nicolas JC, et al. 2005. Estrogenic
136 activity of cosmetic components in reporter cell lines: parabens, UV screens, and musks.
137 *J Toxicol Environ Health A* 68(4): 239-251.
- 138 Gougelet A, Mueller SO, Korach KS, Renoir JM. 2007. Oestrogen receptors pathways to
139 oestrogen responsive elements: the transactivation function-1 acts as the keystone of
140 oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha. *J Steroid
141 Biochem Mol Biol* 104(3-5): 110-122.
- 142 Gungor T, Chen Y, Golla R, Ma Z, Corte JR, Northrop JP, et al. 2006. Synthesis and
143 characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as
144 selective estrogen receptor beta modulators. *J Med Chem* 49(8): 2440-2455.

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 145 Gutendorf B, Westendorf J. 2001. Comparison of an array of in vitro assays for the
146 assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens
147 and xenoestrogens. *Toxicology* 166(1-2): 79-89.
- 148 Harris DM, Besselink E, Henning SM, Go VLW, Heber D. 2005. Phytoestrogens induce
149 differential estrogen receptor alpha- or beta-mediated responses in transfected breast
150 cancer cells. *Experimental Biology and Medicine* 230(8): 558-568.
- 151 Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, et al.
152 2009. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription,
153 p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-
154 small cell lung cancer cells. *J Steroid Biochem Mol Biol* 116(1-2): 102-109.
- 155 Hillerns P, Zu Y, Fu Y-J, Wink M. 2005. Binding of Phytoestrogens to Rat Uterine
156 Estrogen Receptors and
157 Human Sex Hormone-binding Globulins. In: Verlag der Zeitschrift für Naturforschung,
158 649-656.
- 159 Hirsch K, Atzmon A, Danilenko M, Levy J, Shironi Y. 2007. Lycopene and other
160 carotenoids inhibit estrogenic activity of 17beta-estradiol and genistein in cancer cells. In:
161 *Breast Cancer Res Treat*, 221-230. Epub 2006 Oct 2019.
- 162 Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, et al. 2006. Isoflavone
163 metabolites and their in vitro dual functions: they can act as an estrogenic agonist or
164 antagonist depending on the estrogen concentration. *J Steroid Biochem Mol Biol* 101(4-
165 5): 246-253.
- 166 Innocenti G, Vegeto E, Dall'Acqua S, Ciana P, Giorgetti M, Agradi E, et al. 2007. In
167 vitro estrogenic activity of Achillea millefolium L. In: *Phytomedicine*, 147-152. Epub
168 2006 Jul 2024.
- 169 Jordan VC, Jeng MH, Catherino WH, Parker CJ. 1993. The estrogenic activity of
170 synthetic progestins used in oral contraceptives. *Cancer* 71(4 Suppl): 1501-1505.
- 171 Joung K, Kim Y, Sheen Y. 2003. Assessment of the Estrogenicity of Isoflavonoids,
172 Using MCF-
173 7-ERE-Luc Cells. *Arch Pharm Res* 26(9): 756-762.
- 174 Jung J, Ishida K, Nishikawa J, Nishihara T. 2007. Inhibition of estrogen action by 2-
175 phenylchromone as AhR agonist in MCF-7 cells. *Life sciences* 81(19-20): 1446-1451.
- 176 Klinge CM, Risinger KE, Watts MB, Beck V, Eder R, Jungbauer A. 2003. Estrogenic
177 activity in white and red wine extracts. *J Agric Food Chem* 51(7): 1850-1857.
- 178 Kojima H, Katsura E, Takeuchi S, Niiyama K, Kobayashi K. 2004. Screening for
179 estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene
180 assays using Chinese hamster ovary cells. *Environmental Health Perspectives* 112(5):
181 524-531.

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 182 Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lytle CR. 2005.
183 Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.
184 Endocrinology 146(9): 3999-4008.
- 185 Kurosawa T, Hiroi H, Tsutsumi O, Ishikawa T, Osuga Y, Fujiwara T, et al. 2002. The
186 activity of bisphenol A depends on both the estrogen receptor subtype and the cell type.
187 Endocr J 49(4): 465-471.
- 188 Kuruto-Niwa R, Ito T, Goto H, Nakamura H, Nozawa R, Terao Y. 2007. Estrogenic
189 activity of the chlorinated derivatives of estrogens and flavonoids using a GFP expression
190 system. Environmental Toxicology and Pharmacology 23(1): 121.
- 191 Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, et al. 2009.
192 Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol
193 Nutr Food Res 53(7): 845-858.
- 194 Larrosa M, Gonzalez-Sarrias A, Garcia-Conesa MT, Tomas-Barberan FA, Espin JC.
195 2006. Urolithins, ellagic acid-derived metabolites produced by human colonic microflora,
196 exhibit estrogenic and antiestrogenic activities. J Agric Food Chem 54(5): 1611-1620.
- 197 Leblanc K, Sexton E, Parent S, Belanger G, Dery MC, Boucher V, et al. 2007. Effects of
198 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines
199 in the presence and absence of exogenous estrogens. Int J Oncol 30(2): 477-487.
- 200 Lemaire G, Mnif W, Mauvais P, Balaguer P, Rahmani R. 2006. Activation of alpha- and
201 beta-estrogen receptors by persistent pesticides in reporter cell lines. Life sciences
202 79(12): 1160-1169.
- 203 Leung LK, Po LS, Yuen YM. 2004. Effect of dietary flavonols on oestrogen receptor
204 transaction and cell death induction. British Journal of Nutrition 91(6): 831-839.
- 205 Liu S, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S. 2006. Aryl hydrocarbon
206 receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells.
207 In: Biol Chem, 1209-1213.
- 208 Long X, Fan M, Bigsby RM, Nephew KP. 2008. Apigenin inhibits antiestrogen-resistant
209 breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen
210 receptor-alpha-independent mechanisms. Mol Cancer Ther 7(7): 2096-2108.
- 211 Lui K, Tamura T, Mori T, Zhou D, Chen S. 2008. MCF-7aro/ERE, a novel cell line for
212 rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands. Biochem
213 Pharmacol 76(2): 208-215.
- 214 Maggiolini M, Bonofoglio D, Marsico S, Panno ML, Cenni B, Picard D, et al. 2001.
215 Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent
216 effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol 60(3):
217 595-602.

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 218 Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V, et al. 2004.
219 Oestrogen receptor b is required for androgen-stimulated proliferation of LNCaP prostate
220 cancer cells. *Journal of Molecular Endocrinology* 32(3): 777-791.
- 221 Mak P, Leung YK, Tang WY, Harwood C, Ho SM. 2006. Apigenin suppresses cancer
222 cell growth through ERbeta. *Neoplasia* 8(11): 896-904.
- 223 Maru BS, Tobias JH, Rivers C, Caunt CJ, Norman MR, McArdle CA. 2009. Potential use
224 of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective
225 estrogenic activity. *Bone* 44(1): 102-112.
- 226 Nakamura T, Katsu Y, Watanabe H, Iguchi T. 2008. Estrogen receptor subtypes
227 selectively mediate female mouse reproductive abnormalities induced by neonatal
228 exposure to estrogenic chemicals. In: *Toxicology*, 117-124. Epub 2008 Sep 2013.
- 229 Ni YD, Hong WJ, Zhou YC, Grossmann R, Zhao RQ. 2010. Dual effects of daidzein on
230 chicken hepatic vitellogenin II expression and estrogen receptor-mediated transactivation
231 in vitro. *Steroids*.
- 232 Nose T, Tokunaga T, Shimohigashi Y. 2009. Exploration of endocrine-disrupting
233 chemicals on estrogen receptor alpha by the agonist/antagonist differential-docking
234 screening (AADS) method: 4-(1-adamantyl)phenol as a potent endocrine disruptor
235 candidate. In: *Toxicol Lett*, 33-39. Epub 2009 Aug 2008.
- 236 Oh SM, Kim YP, Chung KH. 2006. Biphasic effects of kaempferol on the estrogenicity
237 in human breast cancer cells. *Arch Pharm Res* 29(5): 354-362.
- 238 Overk CR, Peng KW, Asghedom RT, Kastrati I, Lantvit DD, Qin Z, et al. 2007.
239 Structure-activity relationships for a family of benzothiophene selective estrogen receptor
240 modulators including raloxifene and arzoxifene. *ChemMedChem* 2(10): 1520-1526.
- 241 Park SH, Kim KY, An BS, Choi JH, Jeung EB, Leung PC, et al. 2009. Cell growth of
242 ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent
243 pathway, but their stimulation of cell growth appears not to be involved in the activation
244 of the mitogen-activated protein kinases ERK-1 and p38. In: *J Reprod Dev*, 23-29. Epub
245 2008 Oct 2015.
- 246 Pillon A, Servant N, Vignon F, Balaguer P, Nicolas JC. 2005. In vivo bioluminescence
247 imaging to evaluate estrogenic activities of endocrine disrupters. *Anal Biochem* 340(2):
248 295-302.
- 249 Preuss TG, Gurer-Orhan H, Meerman J, Ratte HT. 2010. Some nonylphenol isomers
250 show antiestrogenic potency in the MVLN cell assay. *Toxicol In Vitro* 24(1): 129-134.
- 251 Pugazhendhi D, Watson KA, Mills S, Botting N, Pope GS, Darbre PD. 2008. Effect of
252 sulphation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein
253 in MCF-7 human breast cancer cells. *J Endocrinol* 197(3): 503-515.

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 254 Radice S, Chiesara E, Frigerio S, Fumagalli R, Parolaro D, Rubino T, et al. 2006.
255 Estrogenic effect of procydnone through activation of MAPK in MCF-7 breast
256 carcinoma cell line. *Life Sci* 78(23): 2716-2723. .
- 257 Rey-Roldan EB, Grillo CA, Pietranera L, Libertun C, Nicola AF, Piroli GG. 2008.
258 Levonorgestrel antagonism on estrogen-induced pituitary tumors is mediated by
259 progesterone receptors. In: *Horm Metab Res*, 245-250.
- 260 Rider CV, Hartig PC, Cardon MC, Wilson VS. 2009a. Comparison of chemical binding
261 to recombinant fathead minnow and human estrogen receptors alpha in whole cell and
262 cell-free binding assays. In: *Environ Toxicol Chem*, 2175-2181.
- 263 Rider CV, Hartig PC, Cardon MC, Wilson VS. 2009b. Development of a competitive
264 binding assay system with recombinant estrogen receptors from multiple species.
265 *Toxicology letters* 184(2): 85-89.
- 266 Schreihof DA. 2005. Transcriptional regulation by phytoestrogens in neuronal cell
267 lines. *Mol Cell Endocrinol* 231(1-2): 13-22.
- 268 Seo HS, DeNardo DG, Jacquot Y, Laios I, Vidal DS, Zambrana CR, et al. 2006.
269 Stimulatory effect of genistein and apigenin on the growth of breast cancer cells
270 correlates with their ability to activate ER alpha. *Breast Cancer Res Treat* 99(2): 121-134.
- 271 Shaw LE, Sadler AJ, Pugazhendhi D, Darbre PD. 2006. Changes in oestrogen receptor-
272 alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant
273 (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. *J Steroid Biochem Mol Biol*
274 99(1): 19-32.
- 275 Shen O, Du G, Sun H, Wu W, Jiang Y, Song L, et al. 2009. Comparison of in vitro
276 hormone activities of selected phthalates using reporter gene assays. In: *Toxicol Lett*, 9-
277 14. Epub 2009 Jul 2028.
- 278 Sonneveld E, Riteco JA, Jansen HJ, Pieterse B, Brouwer A, Schoonen WG, et al. 2006.
279 Comparison of in vitro and in vivo screening models for androgenic and estrogenic
280 activities. In: *Toxicol Sci*, 173-187. Epub 2005 Oct 2012.
- 281 Sotoca AM, Ratman D, van der Saag P, Strom A, Gustafsson JA, Vervoort J, et al. 2008.
282 Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells
283 depends on the ERalpha/ERbeta ratio. *J Steroid Biochem Mol Biol* 112(4-5): 171-178.
- 284 Sumida K, Ooe N, Saito K, Kaneko H. 2003. Limited species differences in estrogen
285 receptor alpha-mediated reporter gene transactivation by xenoestrogens. *Journal of*
286 *Steroid Biochemistry and Molecular Biology* 84(1): 33-40.
- 287 Sun H, Xu XL, Qu JH, Hong X, Wang YB, Xu LC, et al. 2008. 4-Alkylphenols and
288 related chemicals show similar effect on the function of human and rat estrogen receptor
289 alpha in reporter gene assay. *Chemosphere* 71(3): 582-588.

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 290 Takayanagi S, Tokunaga T, Liu X, Okada H, Matsushima A, Shimohigashi Y. 2006.
291 Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor
292 gamma (ERR γ) with high constitutive activity. In: Toxicol Lett, 95-105. Epub 2006
293 Sep 2003.
- 294 Takeuchi S, Iida M, Kobayashi S, Jin K, Matsuda T, Kojima H. 2005. Differential effects
295 of phthalate esters on transcriptional activities via human estrogen receptors alpha and
296 beta, and androgen receptor. Toxicology 210(2-3): 223-233.
- 297 Takeuchi S, Takahashi T, Sawada Y, Iida M, Matsuda T, Kojima H. 2009. Comparative
298 study on the nuclear hormone receptor activity of various phytochemicals and their
299 metabolites by reporter gene assays using Chinese hamster ovary cells. Biol Pharm Bull
300 32(2): 195-202.
- 301 Tang X, Zhu X, Liu S, Nicholson RC, Ni X. 2008. Phytoestrogens induce differential
302 estrogen receptor beta-mediated responses in transfected MG-63 cells. Endocrine 34(1-
303 3): 29-35.
- 304 ter Veld MG, Schouten B, Louisse J, van Es DS, van der Saag PT, Rietjens IM, et al.
305 2006. Estrogenic potency of food-packaging-associated plasticizers and antioxidants as
306 detected in ERalpha and ERbeta reporter gene cell lines. J Agric Food Chem 54(12):
307 4407-4416.
- 308 Tezuka Y, Takahashi K, Suzuki T, Kitamura S, Ohta S, Nakamura S, et al. 2007. Novel
309 metabolic pathways of p-n-nonylphenol catalyzed by cytochrome P450 and estrogen
310 receptor binding activity of new metabolites. Journal of Health Science 53(5): 552.
- 311 Van den Belt K, Berckmans P, Vangenechten C, Verheyen R, Witters H. 2004.
312 Comparative study on the in vitro/in vivo estrogenic potencies of 17[β]-estradiol,
313 estrone, 17[α]-ethynodiol and nonylphenol. Aquatic Toxicology 66(2): 183-195.
- 314 Vivacqua A, Recchia AG, Fasanella G, Gabriele S, Carpino A, Rago V, et al. 2003. The
315 food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor
316 alpha in MCF7 breast cancer cells. Endocrine 22(3): 275-284.
- 317 Wang J, Fang F, Huang Z, Wang Y, Wong C. 2009a. Kaempferol is an estrogen-related
318 receptor alpha and gamma inverse agonist. FEBS Lett 583(4): 643-647.
- 319 Wang P, Wen Y, Han GZ, Sidhu PK, Zhu BT. 2009a. Characterization of the oestrogenic
320 activity of non-aromatic steroids: are there male-specific endogenous oestrogen receptor
321 modulators? Br J Pharmacol 158(7): 1796-1807. Epub .
- 322 Wijayaratne A, Nagel S, Paiger L, Christensen D, Norris J, Fowlkes D, et al. 1999.
323 Comparative Analyses of Mechanistic Differences Among Antiestrogens. Endocrinology
324 140: 5828-5840.

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

- 325 Wilkinson JM, Hayes S, Thompson D, Whitney P, Bi K. 2008. Compound profiling
326 using a panel of steroid hormone receptor cell-based assays. *J Biomol Screen* 13(8): 755-
327 765..
- 328 Willemsen P, Scippo ML, Kausel G, Figueroa J, Maghuin-Rogister G, Martial JA, et al.
329 2004. Use of reporter cell lines for detection of endocrine-disrupter activity. *Anal Bioanal*
330 *Chem* 378(3): 655-663.
- 331 Witters H, Freyberger A, Smits K, Vangenechten C, Lofink W, Weimer M, et al. 2010.
332 The assessment of estrogenic or anti-estrogenic activity of chemicals by the human stably
333 transfected estrogen sensitive MELN cell line: results of test performance and
334 transferability. *Reprod Toxicol* 30(1): 60-72.
- 335 Wong SP, Li J, Shen P, Gong Y, Yap SP, Yong EL. 2007. Ultrasensitive cell-based
336 bioassay for the measurement of global estrogenic activity of flavonoid mixtures
337 revealing additive, restrictive, and enhanced actions in binary and higher order
338 combinations. *Assay Drug Dev Technol* 5(3): 355-362.
- 339 Wu F, Safe S. 2007. Differential activation of wild-type estrogen receptor alpha and C-
340 terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer
341 cells. In: *J Steroid Biochem Mol Biol*, 1-9.
- 342 Xu H, Kraus WL, Shuler ML. 2008. Development of a stable dual cell-line GFP
343 expression system to study estrogenic endocrine disruptors. In: *Biotechnol Bioeng*, 1276-
344 1287.
- 345 Yamasaki K, Takeyoshi M, Yakabe Y, Sawaki M, Imatanaka N, Takatsuki M. 2002.
346 Comparison of reporter gene assay and immature rat uterotrophic assay of twenty-three
347 chemicals. *Toxicology* 170(1-2): 21-30.
- 348 Yoon K, Pallaroni L, Stoner M, Gaido K, Safe S. 2001. Differential activation of wild-
349 type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic
350 compounds using a promoter containing three estrogen-responsive elements. *Journal of*
351 *Steroid Biochemistry and Molecular Biology* 78(1): 25-32.
- 352 Yoon K, Pellaroni L, Ramamoorthy K, Gaido K, Safe S. 2000. Ligand structure-
353 dependent differences in activation of estrogen receptor ? in human HepG2 liver and U2
354 osteogenic cancer cell lines. *Molecular and Cellular Endocrinology* 162(1-2): 211-220.
- 355 Yu Y, Zhou Q, Hang Y, Bu X, Jia W. 2007. Antiestrogenic effect of 20S-protopanaxadiol
356 and its synergy with tamoxifen on breast cancer cells. *Cancer* 109(11): 2374-2382.
- 357 Zhao L, Mao Z, Brinton RD. 2009. A select combination of clinically relevant
358 phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective
359 activities in vitro and in vivo. *Endocrinology* 150(2): 770-783.
- 360 Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. 2006. Quantitative structure-activity
361 relationship of various endogenous estrogen metabolites for human estrogen receptor

PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE

362 alpha and beta subtypes: Insights into the structural determinants favoring a differential
363 subtype binding. Endocrinology 147(9): 4132-4150.

364 Zierau O, Kolba S, Olff S, Vollmer G, Diel P. 2006. Analysis of the promoter-specific
365 estrogenic potency of the phytoestrogens genistein, daidzein and coumestrol. Planta
366 Medica 72(2): 184-186.

367